Key Highlights
- PurISTSM test: First CPT code for an algorithm-only analysis.
- Effective date: October 1, 2024.
- Clinical impact: Supports first-line therapy management for PDAC.
- RNA profiling: Essential for personalized cancer treatment.
- Reimbursement milestone: PLA code enhances financial feasibility.
Source: Business Wire
Notable Quote
- “Tempus has been a leader in RNA profiling since its inception. We believe our RNA-based offerings are increasingly valuable as the burgeoning field of RNA-directed therapeutics is set to revolutionize cancer care and rare disease indications.” — Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus AI
SoHC's Take
Tempus AI’s achievement in securing a PLA code for the PurISTSM algorithm represents a significant advancement in the field of precision medicine. This milestone not only highlights the growing importance of RNA profiling in clinical settings but also sets the stage for more robust reimbursement mechanisms for AI-driven diagnostic tools. The ability of PurISTSM to stratify pancreatic cancer patients and inform treatment decisions underscores the transformative potential of integrating advanced algorithms into routine clinical practice. As more RNA-based assays gain recognition and reimbursement, we can expect a substantial shift towards personalized cancer therapies, ultimately leading to better patient outcomes and more efficient healthcare delivery.
